[1] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol, 2011, 55:245-264.
[2] Omata M, Kanda T, Yokosuka O, et al. Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. Hepatol Int, 2015, 9:486-507.
[3] Chen YS, Li L, Cui FQ, et al. A sero-epidemiological study on hepatitis C in China Zhonghua. Liu Xing Bing Xue Za Zhi, 2011, 32:888-891.
[4] 中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2015年更新版). 临床肝胆病杂志, 2015, 31:1961-1979.
[5] Giannini EG, Basso M, Savarino V,et al.Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. J Intern Med, 2009, 266:537-546.
[6] Larrat S, Vallet S, David -Tchouda S, et al. Naturally occurring resistance-associated variants of hepatitis C virus protease inhibitors in poor responders to pegylated interferon-ribavirin. J Clin Microbiol, 2015, 53:2195-2202.
[7] Premoli C, Aghemo A. Directly acting antivirals against hepatitis C virus: mechanisms of action and impact of resistant associated variants. Minerva Gastroenterol Dietol, 2016, 62:76-87.
[8] Cleo Study Group, Ascione A, Adinolfi LE, et al. Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience.World J Hepatol, 2016, 8:949-56.
[9] Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-na?ve genotype 1 hepatitis C: The randomized PILLAR study. Hepatology, 2013, 58: 1918-1929.
[10] Bhatia HK, Singh H, Grewal N, et al. Sofosbuvir: A novel treatment option for chronic hepatitis C infection . J Pharmacol Pharmacother, 2014, 5:278-284 .
[11] Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med, 2014, 370:1889-1898.
[12] Lawit E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet, 2014, 384:1756-1765.
[13] Gray E, O′Leary A, Bergin C, et al. Effectiveness of interferon-free therapy for the treatment of HCV-patients with compensated cirrhosis treated through the Irish early access program. Expert Rev Gastroenterol Hepatol, 2017, 11:593-601.
[14] Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature, 2010, 465:96-100.
[15] Hézode C, Lebray P, De Ledinghen V, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. Liver Int, 2017, 37:1314-1324.
[16] Ishigami M, Hayashi K, Honda T, et al. Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by HCV genotype 1b infection: Real world data. J Gastroenterol Hepatol, 2017.
[17] Kondili LA, Gaeta GB, Leluzzi D, et al, Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS One, 2017, 12:e0172159.
[18] H ner Zu Siederdissen C, Maasoumy B, Marra F, et al. Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis, 2016, 62:561-567.
[19] Kohli A, Alshati A, Georgie F, et al. Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease. Therap Adv Gastroenterol, 2016, 9:887-897.
[20] Lontok E, Harrington P, Howe A, et al. Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology, 2015, 62:1623-1632.
[21] Kliemann DA, Tovo CV, da Veiga AB, et al. Polymorphisms and resistance mutations of hepatitis C virus on sequences in the European hepatitis C virus database. World J Gastroenterol, 2016, 22:8910-8917.
[22] Kai Y, Hikita H, Morishita N, et al. Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment. Sci Rep, 2017, 7:41660.
[23] De Monte A, Courjon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol, 2016, 78:27-30 .
[24] Reig M, Mari o Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol, 2016, 65:719-26.
[25] Yang JD, Aqel BA, Pungpapong S, et al. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol, 2016, 65:859-60.
[26] Strazzulla A, Iemmolo RMR, Carbone E,et al. The risk of hepatocellular carcinoma after directly acting antivirals for hepatitis C virus treatment in liver transplanted patients: Is it real? Hepat Mon, 2016, 16: e41933.
[27] Lee H, Jeong M, Oh J, et al. Preclinical evaluation of multi antigenic HCV DNA vaccine for the prevention of Hepatitis C virus infection. Sci Rep, 2017, 7:43531.
[28] Moon JS, Lee SH, Kim EJ, et al. Inhibition of hepatitis C virus in mice by a small interfering RNA targeting a highly conserved sequence in viral IRES pseudoknot. PLoS One, 2016, 11:e0146710.
[29] Ji C, Liu Y, Pamulapati C, et al. Prevention of hepatitis C virus infection and spread in human liver chimeric mice by an anti-CD81 monoclonal antibody. Hepatology, 2015, 61:1136-1144.
[30] Torrecilla J, Del Pozo-Rodríguez A, Solinís M , et al. Silencing of hepatitis C virus replication by a non-viral vector based on solid lipid nanoparticles containing a shRNA targeted to the internal ribosome entry site (IRES). Colloids Surf B Biointerfaces, 2016, 146:808-817.
|
